相关实验视频
Updated: Jul 23, 2025
00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.4K
氨酸通过PI3K/Akt/mTOR通路调节巨细胞极化和功能来抑制瘤生长
Hyeonha Jang1,2, Uttam Ojha1,2, Ji-Hak Jeong1,2
1Vessel-Organ Interaction Research Center (VOICE, MRC), College of Pharmacy, Kyungpook National University, Daegu, 41566, Republic of Korea.
Archives of pharmacal research
|July 19, 2023
概括
素是一种天然化合物,通过抑制M2型瘤相关巨细胞 (TAMs) 和通过PI3K/Akt/mTOR途径重塑瘤微环境 (TME) 来抑制瘤生长.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤微环境 (TME) 中的瘤相关巨细胞 (TAM) 促进瘤进展,血管生成,转移和治疗抵抗.
- 肌素是一种天然化合物,具有免疫抑制和抗瘤特性,但其对TAM的影响尚不清楚.
研究的目的:
- 为了研究髓素对TAMs和TAM介导的瘤生长的影响.
- 在体外和体内阐明髓素对TAMs作用的潜在机制.
主要方法:
- 评估了氨酸对单细胞-巨细胞分化和两极化 (M1/M2) 的影响.
- 分析了M2巨细胞中的细胞因子表达,益血管性因子分泌和内皮细胞透性.
- 研究了M2巨细胞中的PI3K/Akt/mTOR信号通路.
- 评估了myriocin对TAM群体在小鼠全移植瘤模型中的影响.
- 检查了myriocin和cisplatin对瘤生长和存活的协同作用.
主要成果:
- 氨酸抑制了单细胞-巨细胞分化和M2极化,但没有抑制M1极化.
- 髓素抑制了与巨细胞相关的M2抗炎细胞因子和益血管原因子 (例如,VEGF).
- 氨酸在体内减少了类似M2的TAM,并抑制了M2巨细胞中的PI3K/Akt/mTOR通路.
- 结合米里奥辛和西斯普拉丁治疗协同抑制了瘤生长,并通过减少M2类TAMs来改善存活率.
结论:
- 髓素通过抑制M2类TAM分化和两极化来抑制瘤生长.
- PI3K/Akt/mTOR信号通路是myriocin抗TAM作用的关键目标.
- 髓素显示出作为重塑TME和增强抗癌疗法的治疗剂的潜力.
更多相关视频
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:17The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K